Interview: Joerg Moeller, Bayer Development Chief, On R&D Consolidation
Executive Summary
Scrip caught up with Joerg Moeller, head of development at Bayer Pharmaceuticals, during the company's annual media day. Soon to take leadership of the German group's entire R&D organization, he talked about Bayer's R&D strategy and how the pharma industry will need to work with other healthcare stakeholders more collaboratively.
You may also be interested in...
Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases
The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.
Bayer Shrugs Off Xofigo Sales Pressure From Study Halt
Amid turmoil at Bayer's R&D unit, the company revealed that a Phase III trial of Xofigo had thrown up a safety issue for the product. Bayer insists peaks sales will be unaffected, but what had been a large potential new patient population now looks unlikely.
As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA
Failure of RUBY and ONYX combo trials with Eylea and nesvacumab fan concerns over longer-term growth prospects for Regeneron's ophthalmic franchise.